Rapid Screening Method for Antisense Oligonucleotides Against Human Growth Factor Receptor p185 erbB-2
- 1 March 2004
- journal article
- research article
- Published by SAGE Publications in Oligonucleotides
- Vol. 14 (1) , 1-9
Abstract
The aim of this study was the development of an indirect cell proliferation assay as screening tool for antisense oligonucleotides. Unmodified and phosphorothioate-modified oligonucleotides with different amounts of sulfur in the DNA backbone were examined for biologic activity. The human growth factor receptor p185erbB-2 was chosen as cellular target. High-level expression of this protein can be related to an early event in tumor development and cell proliferation. We correlated the expression of p185erbB-2 with the cell proliferation of BT-474. Additionally a control cell line (MCF-7) with very low p185erbB-2 expression was cultivated. Antisense oligonucleotides were transfected as a liposome formulation (Lipofectin®, GIBCO-BRL, Eggenstein, Germany). Cell count was correlated with a total protein quantification assay (BCA method). Stability against nuclease digestion was determined with a DNase I assay. Sequence-specific antisense effects on the p185erbB-2 protein level were determined by Western blot. An antisense phosphorothioate oligonucleotide was identified to inhibit the cell proliferation in comparison to a random control and a negative control oligonucleotide sequence. The comparison of fully thioated, partly thioated, and unmodified oligonucleotides verified the correlation between the enzymatic stability and the biologic activity of the different modifications. Using the unstable oligonucleotides, more treatments were necessary to achieve an antiproliferative effect. In our study, the indirect proliferation assay was found to be a reliable and potent tool for an antisense oligonucleotide screening by targeting the p185erbB-2 protein.Keywords
This publication has 24 references indexed in Scilit:
- Activation with CpG-A and CpG-B Oligonucleotides Reveals Two Distinct Regulatory Pathways of Type I IFN Synthesis in Human Plasmacytoid Dendritic CellsThe Journal of Immunology, 2003
- Expression of c‐erbB receptors, heregulin and oestrogen receptor in human breast cell linesInternational Journal of Cancer, 2000
- Delineation of a CpG Phosphorothioate Oligodeoxynucleotide for Activating Primate Immune Responses In Vitro and In VivoThe Journal of Immunology, 2000
- Mechanisms and applications of immune stimulatory CpG oligodeoxynucleotidesBiochimica et Biophysica Acta (BBA) - Gene Structure and Expression, 1999
- A review of issues in the pharmacokinetics and toxicology of phosphorothioate antisense oligonucleotidesBiochimica et Biophysica Acta (BBA) - Gene Structure and Expression, 1999
- Characterization and Modulation of Immune Stimulation by Modified OligonucleotidesAntisense and Nucleic Acid Drug Development, 1997
- Gapped BLAST and PSI-BLAST: a new generation of protein database search programsNucleic Acids Research, 1997
- In Vivo Pharmacokinetics of Phosphorothioate Oligonucleotides Containing Contiguous GuanosinesAntisense and Nucleic Acid Drug Development, 1997
- Oligodeoxynucleotide Modifications Determine the Magnitude of B Cell Stimulation by CpG MotifsAntisense and Nucleic Acid Drug Development, 1996
- Phosphorothioate Oligodeoxynucleotides Bind to Basic Fibroblast Growth Factor, Inhibit Its Binding to Cell Surface Receptors, and Remove It from Low Affinity Binding Sites on Extracellular MatrixJournal of Biological Chemistry, 1995